The nano ointment, which has no foreign rivals, has been made available even in the most underprivileged areas of the country, according to a Wednesday report by IRNA.
Nano-liposomal Amphotericin B (AmB) formulation has been used in medicine production. Dr. Mahmoudreza Jafari has worked on this medicine for nearly 17 years in the Faculty of Pharmacy of Mashhad University of Medical Sciences (MUMS).
All the research conducted for this drug has been conducted at MUMS, a major medical university in northeast Iran. After the product's initial development, clinical phases one to three were carried out in cooperation with the Center for Research and Training in Skin Diseases and Leprosy of Tehran University of Medical Sciences.
Over 30,000 people are annually infected with cutaneous leishmaniasis in Iran. The infectious disease occurs mainly in tropical and subtropical regions. The main cause of the disease is the Leishmania parasite, which is caused by a mosquito bite.
Conventional treatment of cutaneous leishmaniasis in Iran include injections and freezing methods, both of which are painful and hard to supply to impoverished regions, said teh report by the IRNA, adding that the homegrown ointment is much easier to use for the patients in the country.
**7129**4261
Your Comment